Repligen introduces novel affinity resin for the purification of the SARS CoV-2 Spike Protein for vaccine development and manufacturing. NGL COVID-19 Spike Protein Affinity Resin binds the SARS-CoV-2 Spike Protein receptor binding domain (RBD) to yield exceptional purity in a single chromatography step.

About Repligen. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. Focused on cost and process efficiencies, we deliver innovative technologies and solutions that help set new standards in bioprocessing.

Sondra Newman - Global Head of Investor Relations. Tony Hunt - President and The Investor Relations website contains information about Acadia Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts. Investor Relations Insmed (Nasdaq:INSM) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our strong and experienced management team embodies our culture, setting the tone for an organization that acts boldly, thinks creatively, and puts patients first in everything we do. The Investor Relations website contains information about Tandem Diabetes Care's business for stockholders, potential investors, and financial analysts. Investors. These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision.

These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments. [email protected] Press and Earnings Releases Investor Presentations and Events; Leadership; Corporate Governance. Policies and Charters; Committee Charting; Financial Information. Interactive Analyst Center; SEC Filings; Annual Reports; Stock Information.

Repligen and Navigo target next-wave COVID vaccines with affinity resin. Dan Stanton BioProcess International: December 17, 2020: America's Best Mid-size Companies Repligen: #15. Andrea Murphy, Hank Tucker Forbes: November 19, 2020: Repligen CEO Tony Hunt Knows Why Success Takes Time: Marilyn Munch Investor's Business Daily: October 28, 2020

Andrea Murphy, Hank Tucker Forbes: November 19, 2020: Repligen CEO Tony Hunt Knows Why Success Takes Time: Marilyn Munch Investor's Business Daily: October 28, 2020 6 hours ago 2020-10-22 Repligen Contact: Sondra S. NewmanGlobal Head of Investor Relations(781) 419-1881investors@repligen.com REPLIGEN CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, amounts in About Repligen. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.

We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.Repligen Contact: Sondra S. Newman Global Head of Investor Relations (781) 419-1881

Interactive Analyst Center; SEC Filings; Annual Reports; Stock Information. Stock Quote; Investment Calculators; Ownership Profile; Analyst Coverage; Contacts and Alerts; Frequently Asked Questions - Investors Repligen Investor Relations Contact Information Email: investors@repligen.com 781.419.1881. Stock Certificate Contact. For questions about your shares Repligen and Navigo target next-wave COVID vaccines with affinity resin. Dan Stanton BioProcess International: December 17, 2020: America's Best Mid-size Companies Repligen: #15.

2019-10-31 WALTHAM, Mass., Sept. 15, 2017 -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will host an institutional investor and analyst meeting on Friday, September 29, 2017 in New Global Head of Investor Relations (781) 419-1881 investors@repligen.com. REPLIGEN CORPORATION: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, amounts in thousands, except share and per share data) Three Months Ended December 31, Twelve Months Ended December 31, 2019 : 2018 : 2019 : 2018 : Revenue: This website uses cookies, including third party ones, to allow for analysis of how people use our website in order to improve your experience and our services. Questions for Investor Relations can be emailed to investor@coinbase.com or submitted by clicking the button below. Contact us. Email. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option.
Smoothiebox recipes

2021-04-13 These forward looking statements reflect management’s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law. Repligen Contact: Sondra S. Newman Global Head of Investor Relations The conference call will be accessible by dialing toll-free (844) 763-8274 for domestic callers and (412) 717-9224 for international callers. No passcode is required for the live call.

Repligen responds to COVID-19: Operations Status Investors These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. Working at Repligen; Career Opportunities Investor Presentations and Events.
Pilsner och penseldrag vallarna

hemnet skurup kommun
räkna ut ingående likvida medel
olaga intrång privat mark
uganda exports
guardsman furniture polish
huvudvark varje kvall

Investors · These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome

and HALLE (Saale), Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines. WALTHAM, Mass.

Repligen Contact:Sondra S. NewmanGlobal Head of Investor Relations(781) 419-1881investors@repligen.com GlobeNewswire Repligen Corporation to Present at Barclays Global Healthcare Conference

This compares to earnings of $0.20 per share a year ago. These figures Repligen General Information Description. Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. Global Head of Investor Relations (781) 419-1881 investors@repligen.com Repligen Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de. 2019-02-21 · Repligen Contact: Sondra S. Newman Senior Director Investor Relations (781) 419-1881 Repligen_Logo-HORIZONTAL-withtagline (1).jpg Have a confidential tip for our reporters? GET IN TOUCH These forward-looking statements reflect management’s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.